Ireland
--:--IST
Starting soon Observational

A Quick and Reliable Eye Movement Test to Help Diagnose ADHD in Children.

NCT07136259 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Onovis Augenpraxis
Phase
Observational
Started
2025-09-01
Last updated
2025-08-22

Condition(s) studied

Attention Deficit Disorder With Hyperactivity (ADHD)Attention Deficit Disorder (ADD)

Study summary

Attention Deficit Hyperactivity Disorder (ADHD) affects more than 5 % of children and adolescents, with a globally increasing prevalence. The condition imposes a significant burden on affected individuals, their families, and healthcare systems. Early and accurate diagnosis is crucial to ensure timely therapeutic and educational interventions. However, current diagnostic practices rely heavily on clinical interviews and behavioral observations, which are inherently subjective and resource-intensive.

There is a growing need for objective diagnostic tools that can complement or even partially replace current clinical assessments. One promising approach involves eye-tracking technology, as ADHD is associated with altered oculomotor control and attention-related neural circuits. These changes may be reflected in measurable eye movement parameters, including saccadic latency and fixation stability.

This clinical investigation uses a certified, CE-marked medical eye-tracking device (neos™) to assess whether specific eye movement parameters can serve as objective biomarkers for ADHD. Although the device was originally designed to assess visual pathway integrity, it also captures parameters related to attention and executive function through standardized protocols. The test is examiner-independent, non-invasive, and takes approximately 10 minutes.

The study is observational and non-interventional, involving two groups of participants aged 8 to 16: 50 children with a clinically confirmed diagnosis of ADHD and 50 age-matched non-ADHD controls. All participants will complete a single neos™ eye-tracking assessment.

The primary hypothesis is that children with ADHD will demonstrate greater variability in saccadic latency and a higher frequency of large saccades (\> 3°) during fixation compared to controls. These differences will be analyzed as potential diagnostic biomarkers. Diagnostic accuracy will be evaluated using receiver operating characteristic (ROC) analysis, with sensitivity, specificity and area under the curve (AUC) values reported.

Secondary hypotheses include:

Oculomotor parameters derived from the neos™ system can distinguish between ADHD subtypes (predominantly inattentive, hyperactive-impulsive and combined).

Combined oculomotor metrics correlate with ADHD symptom severity, potentially enabling a quantitative assessment of disease burden.

The results of this study could pave the way for the clinical adoption of objective, scalable and rapid diagnostic tools for ADHD. Beyond clinical use, such tools may also be adapted for population screening, telemedicine or integration into consumer-grade technologies such as virtual reality headsets. By validating a market-approved device for a new mental health indication, this study represents a critical step toward bridging research and clinical application in ADHD diagnostics.

Eligibility

Sex
ALL
Min age
8 Years
Max age
16 Years
Healthy volunteers
Accepted
Inclusion criteria: For the ADHD group: * Clinically confirmed diagnosis of ADHD by an expert (e.g., pediatrician, neuropsychologist, pediatric neurologist) * Age between 8 and 16 years * Written informed consent from the participant and/or legal guardian For the control group (non-ADHD): * Age between 8 and 16 years * No suspicion of ADHD * Written informed consent from the participant and/or legal guardian Exclusion Criteria: For both groups: * Medical conditions known to affect ocular motor behavior (e.g., neurological or ophthalmological disorders) * Doubts regarding the accuracy of the ADHD diagnosis (for the ADHD group) * Lack of or questionable informed consent * Suspicion of ADHD in control group participants (reported by parents, examiner, or physician)

Primary outcome measure(s)

  • Saccade frequency during fixation — Baseline
    Number of saccades (eye movements \> 3°) made during a fixation task. This frequency is hypothesized to be higher in children with ADHD than in controls.
  • Variability of saccadic latency — Baseline
    Variability in the time it takes for participants to initiate saccadic eye movements in response to visual stimuli. This parameter is expected to be higher in children with ADHD compared to controls.
  • Sensitivity and Specificity of Composite Oculomotor Biomarker for ADHD Diagnosis — At completion of baseline assessment (Day 0)
    Diagnostic sensitivity and specificity of a composite oculomotor biomarker derived from variables predictive of ADHD. Thresholds for individual parameters (e.g. saccadic latency variability \> 110 ms, saccade frequency during fixation \> 10/minute) will be based on literature and refined using internal study data prior to confirmatory analysis. Thresholds and analysis procedures will be pre-specified in the Statistical Analysis Plan.

Trial sites (1)

FacilityCityRegionStatus
OnovisAugenpraxis Bern Canton of Bern
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07136259 on ClinicalTrials.gov ↗ ← All trials in Switzerland